http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GE-P20217310-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6572ff5df928fd17340eb2a8cb6d8502
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
filingDate 2017-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54ea7c5516588a690cface0d1851d5d7
publicationDate 2021-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber GE-P20217310-B
titleOfInvention Pharmaceutical composition comprising beta blocker, converting enzyme inhibitor and antihypertensive or nsaid
abstract Fixed-combination pharmaceutical composition comprising bisoprolol, perindopril or amlodipine or indapamide or acetylsalicylic acid in the combination with pharmaceutically acceptable filler, as well. At that, bisoprolol, perindopril, amlodipine and indapamide are provided as minigranules, and acetylsalicylic acid – as gastroresident tablet. s
priorityDate 2016-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503133
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2244
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID107807
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556224
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506131
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419536333
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3702
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2162
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2405
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534378

Total number of triples: 42.